Double blind randomized controlled trial of deep brain stimulation for obsessive-compulsive disorder: Clinical trial design.
Deep brain stimulation
Neurosurgery
Obsessive-compulsive disorder
Psychiatry
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
09
10
2020
revised:
14
04
2021
accepted:
16
05
2021
entrez:
30
6
2021
pubmed:
1
7
2021
medline:
1
7
2021
Statut:
epublish
Résumé
Obsessive-compulsive disorder (OCD), a leading cause of disability, affects ~1-2% of the population, and can be distressing and disabling. About 1/3 of individuals demonstrate poor responsiveness to conventional treatments. A small proportion of these individuals may be deep brain stimulation (DBS) candidates. Candidacy is assessed through a multidisciplinary process including assessment of illness severity, chronicity, and functional impact. Optimization failure, despite multiple treatments, is critical during screening. Few patients nationwide are eligible for OCD DBS and thus a multi-center approach was necessary to obtain adequate sample size. The study was conducted over a six-year period and was a NIH-funded, eight-center sham-controlled trial of DBS targeting the ventral capsule/ventral striatum (VC/VS) region. There were 269 individuals who initially contacted the sites, in order to achieve 27 participants enrolled. Study enrollment required extensive review for eligibility, which was overseen by an independent advisory board. Disabling OCD had to be persistent for ≥5 years despite exhaustive medication and behavioral treatment. The final cohort was derived from a detailed consent process that included consent monitoring. Mean illness duration was 27.2 years. OCD symptom subtypes and psychiatric comorbidities varied, but all had severe disability with impaired quality of life and functioning. Participants were randomized to receive sham or active DBS for three months. Following this period, all participants received active DBS. Treatment assignment was masked to participants and raters and assessments were blinded. The final sample was consistent in demographic characteristics and clinical features when compared to other contemporary published prospective studies of OCD DBS. We report the clinical trial design, methods, and general demographics of this OCD DBS sample.
Identifiants
pubmed: 34189335
doi: 10.1016/j.conctc.2021.100785
pii: S2451-8654(21)00086-7
pmc: PMC8219641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100785Informations de copyright
© 2021 The Authors.
Références
Psychol Med. 1999 Jul;29(4):869-78
pubmed: 10473314
Lancet. 1999 Oct 30;354(9189):1526
pubmed: 10551504
Psychiatr Serv. 1998 Mar;49(3):379-81
pubmed: 9525801
Psychol Med. 2014 Aug;44(11):2363-74
pubmed: 24451993
Compr Psychiatry. 2017 Jul;76:79-86
pubmed: 28433854
Br J Psychiatry. 1979 Apr;134:382-9
pubmed: 444788
Am J Psychiatry. 2009 Jun;166(6):728-9; author reply 729-31
pubmed: 19487406
Am J Psychiatry. 2007 Jul;164(7 Suppl):5-53
pubmed: 17849776
Arch Gen Psychiatry. 2008 Aug;65(8):914-21
pubmed: 18678796
Acta Neuropsychiatr. 2007 Dec;19(6):357-61
pubmed: 26953001
JAMA Psychiatry. 2014 Sep;71(9):1066-76
pubmed: 25054836
Depress Anxiety. 2001;14(4):214-8
pubmed: 11754128
Behav Res Ther. 2017 Oct;97:183-188
pubmed: 28822299
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
J Neuropsychiatry Clin Neurosci. 2003 Spring;15(2):187-93
pubmed: 12724460
Am J Psychiatry. 2011 Dec;168(12):1266-77
pubmed: 22193671
Am J Psychiatry. 2020 Mar 1;177(3):265-271
pubmed: 31906709
Mol Psychiatry. 2016 Sep;21(9):1272-80
pubmed: 26303665
J Anxiety Disord. 2016 Aug;42:45-51
pubmed: 27268401
Behav Res Ther. 2007 Feb;45(2):251-61
pubmed: 16631110
Mol Psychiatry. 2010 Jan;15(1):64-79
pubmed: 18490925
Biol Psychiatry. 2018 Sep 1;84(5):355-364
pubmed: 29361268
Psychiatr Clin North Am. 1996 Jun;19(2):179-200
pubmed: 8827185
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Behav Res Ther. 2004 Mar;42(3):293-313
pubmed: 14975771
J Neurosurg. 2013 Mar;118(3):491-7
pubmed: 23240700
CNS Spectr. 2004 Nov;9(11):833-47
pubmed: 15520607
Brain Imaging Behav. 2016 Dec;10(4):1054-1067
pubmed: 26518214
Compr Psychiatry. 2014 Jul;55(5):1195-202
pubmed: 24746527
Compr Psychiatry. 2006 Jul-Aug;47(4):270-5
pubmed: 16769301
Am J Geriatr Psychiatry. 2016 Apr;24(4):320-6
pubmed: 26905044
Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Jan;4(1):27-38
pubmed: 30262337
Clin Neurol Neurosurg. 2014 Apr;119:91-5
pubmed: 24635934
Am J Psychiatry. 2000 Nov;157(11):1858-63
pubmed: 11058486
Biol Psychiatry. 2010 Mar 15;67(6):535-42
pubmed: 20116047
Arch Gen Psychiatry. 2010 Oct;67(10):1061-8
pubmed: 20921122
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
pubmed: 14399272
Stereotact Funct Neurosurg. 2006;84(4):184-9
pubmed: 16912517
Biol Psychiatry. 2005 Mar 1;57(5):510-6
pubmed: 15737666
World J Biol Psychiatry. 2016 Aug;17(5):321-65
pubmed: 27403679
J Leg Med. 2019 Oct-Dec;39(4):335-399
pubmed: 31940252
Psychopharmacol Bull. 1993;29(2):321-6
pubmed: 8290681
Mol Psychiatry. 2021 Jan;26(1):60-65
pubmed: 33144712
Neurosurg Clin N Am. 2003 Apr;14(2):xv-xvi
pubmed: 12856486
J Neurosci. 2011 Jul 13;31(28):10392-402
pubmed: 21753016
Br J Med Psychol. 1959;32(1):50-5
pubmed: 13638508
Psychiatr Danub. 2011 Mar;23(1):21-6
pubmed: 21448093
Neuropsychopharmacology. 2006 Nov;31(11):2384-93
pubmed: 16855529
Arch Gen Psychiatry. 1989 Nov;46(11):1012-6
pubmed: 2510699
J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):410-2
pubmed: 16484657
Am J Psychiatry. 2011 May;168(5):502-10
pubmed: 21285143
PLoS One. 2015 Jul 24;10(7):e0133591
pubmed: 26208305
Prostate Int. 2014 Dec;2(4):182-7
pubmed: 25599074
J Neuropsychiatry Clin Neurosci. 2014 Winter;26(1):81-6
pubmed: 24515679
JAMA Psychiatry. 2018 Oct 1;75(10):1081-1087
pubmed: 30140845